Riskpilot← Back to searchSign inGet full accessVANGEN FYSIOTERAPI AS
ASActiveOrg 926151401Hardangervegen 6, 5705 VossPhysiotherapy activities · NACE 8695Est. 20201 employees
Revenue 2025
NOK 630K
+2% vs 2024
EBITDA margin
8.7%
+28% vs 2024
Equity ratio
-65.2%
Financial strength
Net profit 2025
NOK -39K
+34% vs 2024
| Revenue | NOK 630K | +2% |
| EBITDA | NOK 55K | +28% |
| Net profit | NOK -39K | +34% |
| Total assets | NOK 197K | -27% |
| Equity | NOK -129K | -43% |
| Employees | 1 | — |
Legal name
VANGEN FYSIOTERAPI AS
Org number
926151401
Legal form
Aksjeselskap
NACE code
8695 · Physiotherapy activities
Founded
10. desember 2020
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Company purpose
Drift av gruppepraksis innen fysioterapi og andre produkter/tjenester som naturlig hører sammen med dette, herunder å delta i andre selskap med lignende virksomhet, og kjøp og salg av aksjer eller på annen måte gjøre seg interessert i andre foretak.
Address
Hardangervegen 6, 5705 Voss
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 308 | 414 | 582 | 616 | 630 |
| Staff expenses | −42 | −39 | −41 | −58 | −57 |
| EBITDA | −11 | 55 | 17 | 43 | 55 |
| Depreciation & amort. | −4 | −37 | −63 | −70 | −65 |
| EBIT | −16 | 18 | −45 | −27 | −10 |
| Net financials | −0 | −2 | −31 | −32 | −29 |
| Profit before tax | −16 | 17 | −76 | −59 | −39 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −16 | 17 | −76 | −59 | −39 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 56 | 591 | 352 | 271 | 197 |
| Equity | 28 | 45 | −31 | −90 | −129 |
| Long-term debt | 0 | 400 | 372 | 344 | 313 |
| Short-term debt | 27 | 146 | 11 | 18 | 13 |
| Total debt | 27 | 546 | 383 | 361 | 326 |
EBITDA margin
8.7%
This company
15.8%
Market median
-45% vs market
20212025
Equity ratio
-65.2%
This company
38.2%
Market median
-271% vs market
20212025
Return on equity
-3896000.0%
This company
18.4%
Market median
-21174013% vs market
20212025
Net profit margin
-6.2%
This company
8.1%
Market median
-177% vs market
20212025
Asset turnover
3.19×
This company
1.12×
Market median
+185% vs market
20212025
Debt / equity
2.53×
This company
0.62×
Market median
-308% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SM Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 40% | 40% | 2022 | |
| Individual | 20% | 20% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VANGEN FYSIOTERAPI AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Siren Margrethe Bassøe Bakketun | Chief Executive Officer | 0 companies |
| Gunnvor Lindland Loven | Chairman | 0 companies |